Alliancebernstein L.P. increased its stake in shares of Catalent (NYSE:CTLT) by 10.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 297,174 shares of the company’s stock after purchasing an additional 28,090 shares during the period. Alliancebernstein L.P. owned 0.22% of Catalent worth $12,208,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of CTLT. American Century Companies Inc. raised its position in shares of Catalent by 755.3% during the 4th quarter. American Century Companies Inc. now owns 2,631,643 shares of the company’s stock worth $108,108,000 after purchasing an additional 2,323,971 shares during the last quarter. Eagle Asset Management Inc. raised its position in shares of Catalent by 290.9% during the 3rd quarter. Eagle Asset Management Inc. now owns 1,153,710 shares of the company’s stock worth $47,636,000 after purchasing an additional 858,600 shares during the last quarter. Carillon Tower Advisers Inc. acquired a new position in shares of Catalent during the 4th quarter worth approximately $27,561,000. Hood River Capital Management LLC acquired a new position in shares of Catalent during the 4th quarter worth approximately $16,283,000. Finally, Champlain Investment Partners LLC raised its position in shares of Catalent by 10.9% during the 4th quarter. Champlain Investment Partners LLC now owns 3,043,715 shares of the company’s stock worth $125,036,000 after purchasing an additional 298,015 shares during the last quarter. Hedge funds and other institutional investors own 99.89% of the company’s stock.
In other news, SVP William Downie sold 9,082 shares of the business’s stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $41.80, for a total transaction of $379,627.60. Following the completion of the sale, the senior vice president now directly owns 46,986 shares of the company’s stock, valued at approximately $1,964,014.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.70% of the company’s stock.
CTLT stock opened at $39.40 on Friday. The company has a quick ratio of 1.78, a current ratio of 2.22 and a debt-to-equity ratio of 2.66. The firm has a market capitalization of $5,540.73, a price-to-earnings ratio of 69.12, a price-to-earnings-growth ratio of 2.38 and a beta of 1.54. Catalent has a twelve month low of $27.48 and a twelve month high of $47.87.
Catalent (NYSE:CTLT) last issued its quarterly earnings results on Monday, February 5th. The company reported $0.41 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.10. The company had revenue of $606.30 million during the quarter, compared to the consensus estimate of $565.05 million. Catalent had a return on equity of 23.85% and a net margin of 3.03%. Catalent’s revenue was up 25.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.27 EPS. equities research analysts anticipate that Catalent will post 1.53 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Alliancebernstein L.P. Raises Position in Catalent (CTLT)” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3294897/alliancebernstein-l-p-raises-position-in-catalent-ctlt.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.